Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xenetic Biosciences Inc XBIO

Healthcare Biotechnology
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the... see more

Recent & Breaking News (NDAQ:XBIO)

Xenetic Biosciences Reports Third Quarter Financial Results and Provides Business Update

Business Wire November 15, 2016

Xenetic Biosciences Announces the Closing of its $10M Public Offering

Business Wire November 7, 2016

Xenetic Biosciences Announces Nasdaq Listing of its Common Stock and Pricing of $10M Public Offering

Business Wire November 1, 2016

Xenetic Biosciences Reports Positive Topline Data from Third Cohort of Phase 2 Dose-Escalation Trial of ErepoXen® for Anemia

Business Wire October 10, 2016

Xenetic Biosciences to Present at the Ladenburg Thalmann 2016 Healthcare Conference

Business Wire September 22, 2016

Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer

Business Wire August 19, 2016

Xenetic Biosciences Announces Collaboration with Excivion Ltd., UK, to Develop a Novel Combined Zika and Dengue Vaccine

Business Wire August 18, 2016

Xenetic Biosciences Appoints Jeffrey F. Eisenberg to the Board of Directors

Business Wire July 11, 2016

Xenetic Biosciences Announces Reverse Stock Split in Preparation for Proposed Uplisting to Nasdaq Capital Market

Business Wire June 1, 2016

PJSC Pharmsynthez Completes Follow Up and Data Analysis From a Phase 2 Study of Novel Therapeutic Vaccine Xemys(TM) for Multiple Sclerosis

Marketwired April 1, 2016

Baxalta Commences Phase 1 Clinical Trial of BAX 826, the Company's Second Extended Half-Life Factor VIII Treatment for Hemophilia A

Business Wire March 4, 2016

Xenetic Biosciences Appoints Renowned Chemist and Nobel Laureate, Dr. Roger D. Kornberg, to Board of Directors

Marketwired February 29, 2016

Why An Opko Health, Inc. Reversal Is Nigh

Press Releases February 16, 2016

OPKO Health Acquires Interest in Xenetic

Marketwired February 12, 2016

Xenetic Biosciences, Inc. Enters Into Asset Purchase Agreement With Financing Component for the Rights to Develop, Market and License Oncologic Drug Candidate Virexxa(TM)

GlobeNewswire November 16, 2015

Xenetic Biosciences, Inc.'s Major Strategic Shareholders Enter Into Long Term Lock-Up Agreements

GlobeNewswire October 7, 2015

Xenetic Biosciences Commences Third Cohort of Phase 2 Trials on Drug Candidate ErepoXen(R) for Anemia

GlobeNewswire September 16, 2015

Xenetic Biosciences (XBIO) Contracts With Baxter International Inc Have Been Assigned to Baxalta Incorporated Following the Company Spin Out

GlobeNewswire September 9, 2015

Xenetic Biosciences, Inc. Launches Digital Corporate Communication Channels

GlobeNewswire September 2, 2015

Xenetic Biosciences, Inc. - "Why Global Healthcare Companies Have Invested in Xenetic Biosciences"

Accesswire August 6, 2015